本帖最后由 老马 于 2012-1-13 21:20 编辑 u; h; N6 J% {5 B# i
7 e' `$ s: I* X) z
爱必妥和阿瓦斯丁的比较6 ?7 S& i+ f! S$ \5 W
9 [- T) t) E+ e8 p0 m$ }
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
4 J" H' C6 i5 ~5 T9 U
# z, ?2 L8 Q. ^2 q6 E, q5 e
( u0 k, n! i: V# K' bhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/, a/ r8 l* P8 ]4 y
==================================================
, I" L1 ^+ x1 w" x. V2 XOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, a3 ]% `7 y0 w6 c! P) VPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
9 ^+ W3 Y. l+ X2 e6 I, ^: HResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.1 _& z, d; o8 [: t0 @' Y3 F
|
显身卡
: O: Y. k Z6 g! b5 x, m
